The Filing Desk

GeneDx

WGS · Nasdaq · Health Care · Financials, fiscal 2019 to 2025

WGS · Last close · November 13, 2026
$52.37
Value GeneDx yourself

GeneDx's revenue rose 40.0% to $428 million in fiscal 2025. Its operating margin was −3.1%, up from −7.6% a year earlier. Free cash flow was $14 million. The diluted share count rose 6.5%.

GeneDx Holdings Corp. Latest fiscal year ended December 31, 2025 10-K filed February 23, 2026 · 0001818331-26-000015 Updated
Revenue
$428M
40.0%
Operating margin
−3.1%
4.5 pts
Net income
−$21M
 
Free cash flow
$14M
 
Return on capital
−5.3%
5.1 pts
Market cap
$1.6B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What GeneDx does

GeneDx is a genetic testing company that began in 2000 with scientists from the National Institutes of Health. Its main work is exome and genome sequencing, tests that read a person's genes broadly to find the cause of a disease, mostly rare diseases in children. Older panel tests look only at a preset list of genes, based on a doctor's first guess. The company says broad sequencing is moving closer to the standard of care.

Doctors order the tests for patients, and the company reports results back. Payment comes from third parties, such as private health insurers, managed care organizations and government health plans, so the prices they agree to matter a great deal to it. It has also built a large database of rare disease data, called GeneDx Infinity, which it uses to interpret results and says helps its research and discovery work.

It uses automation and artificial intelligence in reading and reporting genetic variants. The company says it is shaping its business around the idea that exome and genome tests will become the routine way to diagnose genetic disease.

Its biggest risks, as it describes them

  • Not getting enough doctors and patients to keep ordering its tests.
  • Insurers and government plans paying too little, or changing their fee schedules, for its tests.
  • A history of net losses since it began.
  • Competitors or newer technologies that could make its tests less competitive.
  • Losing laboratory capacity to a disaster, or failing to meet laboratory licensing rules.
From GeneDx's annual report on Form 10-K, filed February 23, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

GeneDx lost money in fiscal 2025: a net loss of $21 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments401124130141171
Debt incl. finance leases1130767572
Net debt (negative means net cash)−390−94−54−66−99
Net debt to EBITDA—————
Debt to equity0.0x0.1x0.3x0.3x0.2x
Interest coverage−157.4x−208.2x−59.4x−3.5x−2.0x
Current ratio4.8x1.5x3.1x3.6x2.5x
Quick ratio4.4x1.4x3.0x3.4x2.3x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project GeneDx's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What GeneDx says to expect

  • Full year 2026: revenueReiterating full year 2026 revenue guidance of $475 to $490 million
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 9, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, 3 insiders bought $106.6 million of GeneDx shares on the open market, and 4 insiders sold $21.5 million, $510,879 of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 16, 2026Katherine StuelandChief Executive Officer, DirectorSold10,501$97.61$1.0 millionForm 4
Sep 16, 2026Kevin FeeleyChief Financial OfficerSold3,728$97.61$363,898Form 4
Sep 9, 2026Katherine StuelandChief Executive Officer, DirectorSold3,692$84.22$310,940Form 4
Sep 9, 2026Kevin FeeleyChief Financial OfficerSold1,285$84.22$108,223Form 4
Sep 1, 2026Kevin FeeleyChief Financial OfficerSold372$83.84$31,188Form 4
Jun 16, 2026Katherine StuelandChief Executive Officer, DirectorSold10,501$60.76$638,092Form 4
Jun 16, 2026Kevin FeeleyChief Financial OfficerSold3,729$60.76$226,592Form 4
Jun 9, 2026Katherine StuelandChief Executive Officer, DirectorSold3,639$53.77$195,669Form 4
Jun 9, 2026Kevin FeeleyChief Financial OfficerSold1,266$53.77$68,073Form 4
Jun 5, 2026Eli CasdinDirector, 10% ownerBought50,000$52.86$2.6 millionForm 4
Jun 4, 2026Eli CasdinDirector, 10% ownerBought150,000$56.44$8.5 millionForm 4
Jun 1, 2026Kevin FeeleyChief Financial OfficerSold369$51.74$19,092Form 4
The latest 12 of 44 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 95 of 96 of 9
Rule of 40−105.2%39.7%43.3%
Altman Z''−9.83−7.17−5.22
Accruals ratio1.0%−5.7%−11.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailPass
Return on assets rosePassPassPass
Cash from operations exceeds net incomeFailPassPass
Debt fell relative to assetsFailFailPass
Current ratio rosePassPassFail
Share count didn't riseFailFailFail
Gross margin rosePassPassPass
Revenue rose relative to assetsFailPassPass
F-score3 of 95 of 96 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put GeneDx side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
GeneDxFY2540.0%−3.1%3.3%−5.3%—6
CareDxFY2513.8%−8.1%—−20.0%—4Compare
Starling OncologyFY2527.8%−7.2%−5.5%−75.7%—3Compare
VeracyteFY2516.0%11.2%24.5%6.1%−4.6x6Compare
Castle BiosciencesFY253.7%−12.4%8.2%−19.1%—4Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

7 years of figures

Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue196179212235203305428
Revenue growth—−8.6%18.3%10.6%−13.7%50.8%40.0%
Gross profit834−17−2790194298
Research and development357310586584672
Operating income−30−242−446−668−181−23−13
Net income−30−241−245−549−176−52−21
Diluted EPS (US$)−264,056.00−47,036.00−2.27−53.63−7.23−1.94−0.73
Diluted shares (millions)0010810242729
Cash flow
Cash from operations−19−93−190−319−180−2833
Capital expenditure1224975619
Free cash flow−31−117−200−326−185−3414
Dividends paid0000000
Share buybacks0000000
Acquisitions0001271200
Stock-based compensation612021942−0932
Balance sheet at fiscal year end
Cash and short-term investments115108401124130141171
Debt incl. finance leases—211130767572
Total assets—252554491419419524
Total liabilities—247166237191174216
Shareholders' equity−89−330388254228245308
Margins and ratios
Gross margin42.2%2.2%−7.8%−11.4%44.4%63.6%69.7%
Operating margin−15.5%−134.9%−210.2%−284.5%−89.2%−7.6%−3.1%
Net margin−15.1%−134.6%−115.6%−233.9%−86.8%−17.1%−4.9%
Free cash flow margin−15.6%−65.4%−94.2%−139.0%−91.5%−11.1%3.3%
Rule of 40 (growth + FCF margin)—−74.0%−75.8%−128.4%−105.2%39.7%43.3%
Return on capital———−665.3%−85.4%−10.4%−5.3%
Return on equity——−845.4%−171.1%−73.0%−22.1%−7.6%
Return on assets——−60.9%−105.1%−38.6%−12.5%−4.5%
Net debt to EBITDA———————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: GeneDx's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with GeneDx.